EU's Avastin policy: A stark contrast to the FDA's recent decision

The Wall Street Journal: EU Backs Avastin For Breast Cancer
The committee's decision stands in stark contrast to the recent verdict by the U.S. Food and Drug Administration, which is wary of Avastin's benefits for breast-cancer patients. While the FDA plans to revoke approval of Avastin, the U.S. regulator has granted Roche a hearing later this year, though analysts say the Swiss drug maker is unlikely to change the U.S. watchdog's views (Mijuk, 3/2).

---

This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.